

Recurrent Neural Network (RNN) Model Accelerates the Development of Metronidazole Derivatives Antibacterial

Nannan Chen^{1#}, Lijuan Yang^{2#}, Guiwen Li¹, Jiajing Cai¹, Na Ding¹, Jie Qin^{1*},

Yuzhen Niu^{1*}

¹School of Life Sciences and Medicine, Shandong University of Technology, Zibo,
255049 Shandong, China;

² Institute of modern physics, Chinese Academy of Science, Lanzhou, 730000 Gansu,
China;

These authors contributed equally to this work.

* Corresponding author

Jie, Qin, E-mail: 295722387@qq.com

Yuzhen, Niu, E-mail: niuyzh329@sdut.edu.cn

Bioassay Conditions

Stock solutions of the synthesized compounds (100 µg/mL) in DMSO were prepared, and graded quantities of the test compounds were incorporated in specified quantity of sterilized liquid MH medium. A specified quantity of the medium containing the test compound was poured into microtitration plates. Suspension of the microorganism was prepared to contain approximately 10^5 cfu/mL and applied to microtitration plates with serially diluted compounds in DMSO to be tested and incubated at 37 °C for 24 h. After the MICs were visually determined on each of the microtitration plates, 50 µL of PBS (phosphate buffered saline 0.01 mol/L, pH 7.4, $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ 2.9 g, KH_2PO_4 0.2 g, NaCl 8.0 g, KCl 0.2 g, distilled water 1000 mL) containing 2 mg of MTT/mL was added to each well. Incubation was continued at room temperature for 4–5 h. The content of each well was removed, and 100µL of isopropanol containing 5% 1 mol/L HCl was added to extract the dye. After 12 h of incubation at room temperature, the optical density (OD) was measured with a microplate reader at 550 nm.




Fig. S1. The synthetic routes of 0355 and 0799 predicted by chemical.ai.




Fig. S2 ^1H NMR spectrum of **8a**.




Fig. S3 ¹H NMR spectrum of **8b**.




Fig. S4 ^1H NMR spectrum of **8c**.




Fig. S5 ^1H NMR spectrum of **8d**.




Fig. S6 ^1H NMR spectrum of **8e**.




Fig. S7 ^1H NMR spectrum of **8f**.




Fig. S8 ^1H NMR spectrum of **8g**.




Fig. S9 ^1H NMR spectrum of 8h.




Fig. S10 ^1H NMR spectrum of **8i**.




Fig. S11 ^1H NMR spectrum of **8j**.




Fig. S12 ¹H NMR spectrum of 8k.




Fig. S13 ^1H NMR spectrum of **8l**.

2#134 RT: 0.30 AV: 1 NL: 4.37E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S14 ESI-MS spectrum of **8a**.

3#134 RT: 0.30 AV: 1 NL: 3.44E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S15 ESI-MS spectrum of **8b**.

E1 #134 RT: 0.30 AV: 1 NL: 8.93E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S16 ESI-MS spectrum of **8c**.

4 #54 RT: 0.12 AV: 1 NL: 4.54E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S17 ESI-MS spectrum of **8d**.

5 #134 RT: 0.30 AV: 1 NL: 2.73E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S18 ESI-MS spectrum of **8e**.

6#134 RT: 0.30 AV: 1 NL: 2.57E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S19 ESI-MS spectrum of **8f**.

10 #134 RT: 0.30 AV: 1 NL: 3.57E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S20 ESI-MS spectrum of **8g**.

11 #134 RT: 0.30 AV: 1 NL: 3.85E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S21 ESI-MS spectrum of **8h**.

12 #134 RT: 0.30 AV: 1 NL: 4.20E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S22 ESI-MS spectrum of **8i**.

16 #134 RT: 0.30 AV: 1 NL: 8.07E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S23 ESI-MS spectrum of **8j**.

20 #133 RT: 0.30 AV: 1 NL: 5.45E3
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S24 ESI-MS spectrum of **8k**.

16 #81 RT: 0.18 AV: 1 NL: 1.40E4
T: ITMS + p ESI Full ms [50.00-500.00]




Fig. S25 ESI-MS spectrum of **81**.